Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Add-on clioquinol in drug-resistant epilepsy
2024-511388-27-04Phase 2Completed
- Sponsor
- UZ Leuven
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Clioquinol in epilepsy, sponsored by UZ Leuven. Primary endpoints: 50% responder rate after low- and higher-dose exposure and Median percent reduction in seizure frequency. Started Jul 2024; status: completed.
02
Drugs
Clioquinol
03
Conditions
epilepsy
Beyond the preview
Go deeper on 2024-511388-27-04.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511388-27-04.